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Abstract 
Background: Since cytotoxic T cell (CTL) response is the major cellular type in attacking tumor cells, most immuno-
therapy targets to manipulate the CTL response. Immunotherapies targeting melanoma-specific antigens (MAGEs), 
a group of tumor-specific shared antigen, have shown to be promising. Our previous study has shown that MAGE1/
TBHSP70 and MAGE3/TBHSP70 could induce a robust immune response against B-16 melanoma cells in C57BL/6 
mice. In this study, we used an animal model to further demonstrate MAGEs as a potential immunotherapy target for 
tumorigenesis in vivo.
Methods: In the current study, we developed a MAGE1/MAGE3/TBHSP70 recombinant protein vaccine and evalu-
ated its protective efficacy against tumor development by challenge vaccine-immunized mice with MAGE-expressing 
human tumor cell lines in a Hu-PBL-SCID mouse model. The cellular immune reactions were monitored by ELISPOT 
and cytotoxicity assays.
Results: Splenocytes isolated from vaccine-immunized mice presented potent cytokine secretion capacity and 
CTL-specific cytotoxic. Vaccine-immunized mice had a significant tumor regression and prolonged survival compared 
with controls (both p < 0.05). In vitro, rMAGE1-MAGE3-TBHSP70 showed a potent tumor-antigen-specific immune 
response in both hepatocellular carcinoma and pulmonary carcinoma cell lines.
Conclusion: This newly-developed recombinant protein vaccine may serve as a new immunotherapy for cancer.
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Background
Anti-tumor peptide/protein vaccines have become a 
promising therapeutic approach since such vaccines 
enhance the immune response of body towards the 
specific anti-tumor antigens, and vaccination itself is a 
relatively safe approach in clinical practice [1, 2]. Mela-
noma-associated antigens-A (MAGE-A) family is a group 
of well-characterized cancer/testis antigens (CTA) which 
could serve as a potential candidates for anti-tumor 
vaccines based on the fact that MAGEs are tumor spe-
cific, are shared by many different kinds of tumor and can 
be recognized by autologous cytotoxic T lymphocytes 
(CTLs) [3–6].
Currently, basic research is under way to study the 
mechanism of anti-tumor immunity and how MAGE 
vaccines could play a role in anti-tumor treatment, as 
well as the efficiency and side effects of this therapeutic 
approach [7–9]. Scientists have been making efforts to 
optimize the vaccination strategies, including compar-
ing different linked-adjuvants of the vaccine, engineering 
the regulating gene and combining multiple CTL epitope 
to enhance the efficiency of vaccination. Previously, we 
reported that reconstructed MAGE1-TBHSP70 DNA 
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vaccine and recombinant TBHSP70-MAGE3 protein 
vaccine were sufficient enough in enhancing anti-MAGE 
tumor immunity [10, 11]. However, transient transfected 
animal model was used in that study, which had limited 
clinical application value. Our further investigation sug-
gested that polyvalent immune response is important to 
maintain a sustained reaction targeting tumor growth. 
Data from our study and others indicted that the poly-
valent immune response can modulate antigen expres-
sion on tumor cells and grant tumor cells with capacity 
of being resistant to a single antigen approach anti-tumor 
treatment [12]. Hence, it is interesting and necessary 
to investigate the possibility and efficiency of multiple 
antigen targeting anti-tumor immunotherapy. Thus, we 
engineered, cloned and made a recombinant MAGE1-
MAGE3-TBHSP70 protein targeting two member of 
MAGE family proteins and further studied the thera-
peutic effects of this recombinant vaccine in anti-tumor 
response using a PBL-Hu-SCID model in this study.
Methods
Vectors
The pET28a(+) expression vector (Invitrogen, CA, USA) 
containing the T7 lac promoter was the basic plasmid 
used for protein expression. The MAGE-1 (NCBI Refer-
ence Sequence NM_004988) fragment in CDS sequence 
(500–1150  bp, 651  bp) was amplified by PCR from the 
plasmid pcDNA3-MAGE1 [10]. The amplified product 
was cloned into pET28a(+) downstream of the T7 lac 
promoter containing BamHI and SacI sites. This plas-
mid was then named as pET-M1. The Mycobacterium 
tuberculosis HSP70 gene was amplified from the plasmid 
pcDNA3-HSP70 [10]. The amplified product was further 
cloned into the HindIII and XhoI sites of the pET-M1, 
and the product was named as pET-M1H. The MAGE-3 
(NCBI Reference Sequence NM_005362) fragment in 
CDS sequence (792–1154 bp, 363 bp) was acquired from 
vector pET-MAGE3 [11] using the similar method men-
tioned above. The amplified product was cloned into 
pET28a(+) and pET-M1H with SacI and HindIII sites. 
The product was named as pET-M3 and pET-MMH, sep-
arately. pET-M3 was also cloned into the M. tuberculosis 
HSP70 gene and named as pET-M3H. All the produc-
tions were verified by DNA sequencing (Sangon Co. Lt., 
Shanghai China). All primer design, sequence blast and 
analysis were performed by Vector NTI software (Infor-
max Inc., Maryland, USA).
Expression, purification, and detection
Expression vectors pET-M1H, pET-M3H, pET-MMH 
and the empty plasmid vector pET28a(+) were trans-
fected into Escherichia coli Bl21 (DE3) plysS competent 
cells. The recombinant protein expression was performed 
according to the manufacture manual. Briefly, the culture 
pellets were analyzed by SDS-PAGE, and were purified by 
His GraviTrap™ Flow (Amersham Biosciences, USA) col-
umn containing pre-charged Ni Sepharose™ 6 Fast. Puri-
fied proteins were detected for antigenicity using western 
blot. Primary antibodies used in western blot were rabbit 
polyclonal anti-human MAGE1 (ab21472, Abcam, USA) 
antibody and rabbit polyclonal anti-human MAGE3 
(ab38496, Abcam, USA) antibody whose binding site 
located in the truncated fragments of the expressed pro-
tein. The amino acid sequences were analyzed by mass 
spectrograph.
Animal models and cell lines
The homozygous C.B-17 scid/scid male mice were pur-
chased from Slaccas Laboratory Animal Co. Lt. Shang-
hai China (http://www.slaccas.com) and were housed 
in a micro-isolated environment. The animal protocol 
met the criteria of the NIH guide for the care and use of 
laboratory animals. Hepatocarcinoma cell lines HepG2, 
human hepatocellular carcinoma cell HHCC and pulmo-
nary carcinomas cell line (A549) were carefully selected 
according to virtue of approximate growth curve, dou-
bling time and percent of apoptosis. To verify specific 
immune response, MAGE1 and MAGE3 transcription 
and expression levels in these cell lines were detected 
using western blot and nest-real time polymerase chain 
reaction (net-RT-PCR) according to the standard proto-
cols [13].
Reconstruction of Hu‑PBL SCID
The Hu-PBL SCID mouse model was reconstructed 
according to a previous method with slight modifications 
[14, 15]. Briefly, the mice were pretreated 1 day prior to 
Hu-PBL injection with a single dose of lyophilized anti-
ASGM1 antibody (Wako Chemicals, USA). Anti-ASGM1 
was a rabbit polyclonal Abs that recognized murine NK 
cells, through which it depleted NK cell activity. Prior to 
Hu-PBL engraftment, SCID mice were irradiated with 
2  Gy gamma irradiation from a 60Co linear accelerator. 
The peripheral blood mononuclear cells (PBMC) was iso-
lated from healthy donor’s blood using Ficoll-Hypaque 
centrifugation method and then immediately injected 
(2 × 107 cells in each mouse) intraperitoneally into irradi-
ated mice. The heparinized serum was obtained from the 
mice by tail vein bleeding at 2 to 3-week intervals after 
PBMC injection. The human IgG and mice IgG in serum 
were quantified using enzyme-linked immunosorbnent 
assays (ELISAs). Normal mouse serum and donor serum 
served as controls. The mice were eligible for humanized 
when the concentration of human IgG reached approxi-
mately 3  μg/ml. Mouse with IgG reached 5  μg/ml were 
considered as unsuccessful humanization.
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Vaccination and detection of humoral immunity 
and cellular immunity in Hu‑PBL‑SCID mouse mode
A total of six Hu-PBL SCID mice were finally included in 
each group. Six naive SCID mice (Un-Humanized Mice, 
UnHuM) were included as a control group. In addition, 
the PBL of tuberoculosis patient (TB-PBL) was also 
pooled and tested in  vitro. The mice were immunized 
twice intra-peritoneally (i.p.) at a 2-week interval with 
200  pmol of the purified recombinant proteins diluted 
in 100  μl PBS (0.1  M, pH 7.3). The PBL of tuberoculo-
sis patient (TB-PBL) was incubated with TBHSP70 an 
hour in vitro at 24 h interval for the study of non-specific 
response of vaccine in humanized mouse model.
Heparinized serum was obtained by tail-vein bleed-
ing 1  week after the second vaccination. 96-well plates 
were coated with recombinant protein (5  μg/well) and 
incubated with 100  μl of serially diluted mice serum or 
TB-PBL’s serum. Plates were then incubated with mouse 
anti-human IgG conjugated alkaline phosphatase (AP) 
(Sigma) and the plate was read using a BioRad microplate 
reader at an absorbing wave length of 415 nm.
The splenocytes were harvested and pooled 2  weeks 
after the second vaccination. Human IFN-γ ELISpot 
assay and the IL-2 ELISpot assay were performed using 
Human IFN-γ ELISpot Kit (856 051 005PC, Diaclone, 
Besancon, France) and Human IL-2 ELISpot Kit (856 
001 005PC, Diaclone, Besancon, France) according to the 
manufacturer’s instructions.
Flow cytometry
Single-cell suspensions of splenocytes were stained with 
anti-mouse CD3, CD4, CD8, and CD19 antibodies to 
detect mouse spleen cells. Pooled PBLs were stained with 
the anti-human antibodies: anti-human CD3 (clone SK7), 
CD4 (SK3), CD8 (RPA-T8) and CD19 (4G7). All anti-
bodies were obtained from BD Pharmingen (San Diego, 
CA, USA) cells were analyzed on a FACS Calibur flow 
cytometer.
Cytotoxic assays and tumor cell challenge
The non-radioactive cytotoxicity assay (G1708, Promega, 
USA) was used to quantify the release of a cytosolic 
enzyme, lactate dehydrogenase (LDH) upon the lysis of 
the target cell. Prior to the tumor cell challenge, pooled 
splenocytes (effector cells, E) were incubated with the 
M1H, M3H, MMH recombinant protein (5  mg/ml) for 
2 h at room temperature. The tumor cells (1 × 104 cells/
well) were added to a serial-diluted splenocytes suspen-
sion for 4 h at 37 °C. After centrifugation, 50 μl aliquots 
of the cell-free supernatant were assayed for the LDH 
content. To correct the confounding effect of spontane-
ous LDH release from effector cells, the LDH levels were 
measured at each individual effector cell concentration 
and used in the real experimental setups (effector spon-
taneous). The spontaneous release of LDH from target 
cells (target spontaneous) was also measured. The maxi-
mum target cell LDH release level (target maximum) was 
measured after lysing cells with 0.4 % Triton X-100. This 
level was defined as a 100 % LDH release. The percentage 
of specific LDH release was determined with the follow-
ing formula:
In the tumor growth and survival experiment, 3 weeks 
after the last vaccination, mice were challenged sub-
cutaneously in the groin with 1  ×  106 HepG2, A549 
and HHCC tumor cells.The tumor growth rate was 
monitored twice a week by caliper measurement. 
Tumor volumes (TV) were calculated as follows: 
TV = length × width2 × π/6. A death event was defined 
as having to sacrifice an animal due to excessive tumor 
burden, tumor abscess, or unresponsiveness to stimuli.
Statistical analysis
Survival curves for tumor-free survival were plotted 
using Kaplan–Meier method and difference between 
groups was analyzed using the log-rank test. Cytokine 
responses were presented as mean ± SD. One way analy-
sis of variance (ANOVA) with a Newman-Keuls post hoc 
test was used to compare the difference among three 
groups and the difference between specific two groups. 
Tumor sizes were analyzed using the Mann–Whitney-U 
test. Statistical analyses were performed using GraphPad 
Prism software. For all analyses, two-tail p values below 
0.05 were defined as significantly different.
Results
Recombinant proteins expression, identification 
and detection in tumor cell lines
The expression proteins sequence were predicted as 
model shown in Fig.  1A, while the molecular weight 
were calculated 91,918  Da of M1H, 8,109,861  Da of 
M3H and 106,113  Da of MMH by software. Accessed 
by western blot Gel-Pro Analysis software Image-Pro 
Premier (MediaCybernetics Inc., MD, USA), the molec-
ular weight of M1H, M3H1 and MMH were 92, 86 and 
110  kDa, respectively (Fig.  1B). Using anti-MAGE1 and 
anti-MAGE3 antibodies as a probe for western blot, 
the recombinant proteins M1H and M3H both showed 
epitopes for MAGE1, while rMMH had epitope for both 
MAGE1 and MAGE3 (Fig. 1B, C). The recombinant pro-
teins were further analyzed by mass spectrometry, the 
% cytotoxicity
=
Experimental− Effector spontaneous− Target spontaneous
Target maximum− Target spontaneous
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sequences and molecular mass were both consistent with 
the prediction (data not shown).
We further study whether commonly used tumor cell 
lines including HepG2, A549 and HHCC expressed 
MAGEs family members including MAGE1 and MAGE3. 
HepG2 cells express a 45 kDa protein when blotted with 
anti-MAGE1 antibody (Fig.  1E), but not anti-MAGE3 
antibody. In contrast, A549 tumor cell lines express 
MAGE3 protein with a 48  kDa molecular weight, but 
not MAGE1 (Fig. 1E). HHCC cell line expresses neither 
MAGE1 nor MAGE3 (Fig.  1D). The protein expression 
data is consistence with mRNA transcription levels of 
MAGE1 and MAGE3 in the three different tumor cell 
lines (Fig.  1F). Briefly, nest-RT-PCR showed MAGE1 
mRNA in HepG2 cell line, MAGE3 mRNA in A549 
cell line and neither of these mRNAs in HHCC cell line 
(Fig. 1F). Both protein and mRNA level of MAGE1 and 
MAGE3 in these three tumor cell lines were consistent 
with the report from others [13, 16]. Thus, we concluded 
that HHCC cell neither expressed MAGE-1 nor MAGE-
3, while HepG2 cells highly expressed MAGE1 and A549 
cells expressed MAGE3.
Vaccines boosted splenocytes‑specific CTL proliferation 
and recognition but lacks humoral response
Stimulated splenocytes from vaccine-immunized mice 
with tumor cells induced an increased secretion of IFN-γ 
and IL-2 (Fig.  2). Upon A549 cell stimulation, the sple-
nocytes isolated from rM3H and rMMH vaccinated 
mice secreted higher level IL-2 than PBS control group 
(p = 0.0003) (Fig. 2a), while the increased IFN-γ secretion 
only existed in splenocytes from mice received rM3H vac-
cine (p < 0.05) (Fig. 2d). The same phenomena were also 
observed in splenocytes from mice received rM3H vaccine 
after HepG2 cell stimulation (Fig.  2b, e). After co-incu-
bation splenocytes with HepG2 lysates, the splenocytes 
from mice receiving rM1H vaccine showed a significantly 
increased secretion of cytotoxic cytokine including IL-2 
and IFN-γ (Fig.  2b, e). In contrast, the splenocytes from 
mice receiving rMMH vaccine did not show an increased 
cellular immunity to both HepG2 and A549 stimula-
tion in vitro (Fig. 2c, f ). The rMMH induced secretion of 
cytokines after HepG2 and A549 cells stimulation implied 
a successful initiation of CTL recognition of the MAGE 
portions upon the challenge with different tumor cell lines.
Fig. 1 Vaccine information and MAGEs expression in tumor cell lines. A The expression vector for the recombinant vaccine protein including 
MAEG1-TBHSP70 expression vector (abbr. pET-M1H), MAGE3-TBHSP70 vector (abbr. pET-M3H) and MAGE1-MAEG3-TBHSP70 (abbr. pET-MMH) 
expression vector. B Protein lysates were run through electrophoresis gel and stained with Coomassie. C Purified recombinant proteins were run 
through electrophoresis gel and transferred into PVDF membrane, and then blotted with MAGE1 and MAGE3, showing similar pattern as coomas-
sie staining. D Purified recombinant protein were blot with MAGE1 and MAGE3 separately. E Protein level of MAGE1 and MAGE3 in three different 
tumor cell line including HepG2, A549 and HHCC. F mRNA transcription levels of MAGE1 and MAGE3 in HepG2, A549 and HHCC cell lines using 
nest-RT-PCR
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We further used flow cytometry to investigate the T cell 
activation and proliferation in these vaccine-immunized 
mice when challenged with different tumor cell lines. 
Mice had 18  % CD3+  cells, 17  % CD4+  cells and 20  % 
CD8+  cells before vaccination (PBS control group in 
Fig. 3a–d). After being vaccinated by rM1H, CD3+ cells 
percentage increased to 21 % (Fig. 3a), while CD4+ cells 
increased to 19 % (Fig. 3b), CD8+ cells increased to 25 % 
(Fig.  3c) in A549 cell challenged cells. Similarly, mice 
received rM3H vaccination had a decreased CD3+ frac-
tion (36  %) (Fig.  3a), but an increased CD4+  fraction 
(24 %) (Fig. 3b) and CD8+ fraction (37 %) (Fig. 3c). Simi-
lar phenomena of T cell sub population profile change 
was also observed in mice received rMMH vaccine 
(Fig.  3a–c). We did not observe any difference in CD20 
cells profile between either of the groups in the current 
study (Fig. 3d). Thus, our data provided another evidence 
of increased T cell activation and increased proliferation 
in mice vaccinated with the recombinant protein vac-
cines upon tumor cell challenge.
Effective and specific cellular cytotoxic‑response to tumor 
cells in vitro
To further determine whether recombinant proteins may 
elicit specific cytotoxicity activity in Hu-PBL-SCID mice 
ex  vivo, splenocytes isolated from vaccine-immunized 
mice were re-stimulated in  vitro with recombinant vac-
cines or PBS for 2  h at room temperature. The ratio of 
specific cytolysis to the target cells (E:T ratio) was deter-
mined by a nonradioactive cytotoxicity assay. We found 
that the splenocytes boosted the vaccines efficiency 
and strengthened the cytotoxic-specific cell lysis effect 
to both HepG2 and A549 tumor cells chllenge in  vitro 
(Fig.  4a, b). The rM1H and rMMH both induced the 
attack of immune system towards the tumor cells includ-
ing HepG2 and A549 tumor cells (p  <  0.001) (Fig.  4a, 
b). In contrast, the specific elimination of HHCC tumor 
cells was not obvious in mice receive either vaccine or 
placebo (p < 0.001) (Fig. 4c). These data suggested a role 
of specific tumor cell lysis effect of recombinant vac-
cine-immunized mice from the splenocytes, including 
Fig. 2 Cellular immunity from splenocyte after stimulation. a–c IL-2 levels from mice vaccinated with rM1H, rM3H, MMH and PBS and challenged 
with A549 (a), HepG2 (b) and HHCC (c) cells. d–f IFN-γ levels from mice vaccinated with rM1H, rM3H, MMH and PBS and challenged with A549 (d), 
HepG2 (e) and HHCC (f) cells
Page 6 of 9Junwei et al. Cancer Cell Int  (2016) 16:45 
cell lysis effect of immune system in rM1H-immunized 
mice toward HepG2 tumor cells, rM3H-immunized mice 
towards A549 cells and rMMH-immunized mice towards 
both HepG2 and 549 tumor cells. We did not observe 
a significant change of HHCC tumor cell lysis in mice 
received rMMH vaccination (Fig.  4c). This is consistent 
with our finding that HHCC did not express MAGE1 and 
MAGE3 which consequently could not induce cellular 
cytotoxic-response and anti-tumor lysis effect through 
MAGE family proteins upon HHCC challenge.
Vaccination protected animals from progressive tumors 
growth and higher survival rate after the in vivo tumor cell 
challenge
We carefully measure the tumor volume and follow-
up the survival rate of mice in all groups for a period of 
60  days after the implantation of tumor cells into these 
mice. In PBS group, mice died due to extensive tumor 
load and consequent infection on day 14 before the 
experimental endpoint (Fig. 5a, b). The tumor growth rate 
and survival rate were summarized in Table 1 and Fig. 5. 
Mice received recombinant proteins vaccine rM3H and 
rMMH had a significantly decelerated tumor growth rate 
and better survival rate (Fig. 5a, b, d and e and Table 1). 
In details, the rM1H and the rM3H vaccinated mice had 
a significantly less degree of HepG2 or A549 cell growing 
compared with those without vaccination (both p < 0.05), 
whereas the rMMH-immunized mice was defective in 
both HepG2 and A549 tumor growth (both p  <  0.05) 
(Fig.  5a, b). This suggested that the rMMH vaccination 
induced the bi-antigen-specific immune response in vivo 
and had a protective effect against MAGE-1 or MAGE-3 
positive tumors. The median survival days of rMMH-
immunized mice treated with either HepG2 or A549 
tumor cells was the longest among all groups (Fig. 5d, e 
and Table 1), strongly suggesting a survival-benefit effect 
of either MAGE1 or MAGE3 vaccination in mouse. No 
difference was observed in either tumor cell growth rate 
or the survival rate in mice challenged with HHCC and 
PBS (Fig. 5c, f ).
Discussion
It is well known that the MAGE family is not only a tumor 
specific antigen but is associated with tumor invasion, 
metastasis, and patient survival [17, 18]. MAGE-based 
cancer vaccines are proposed to exert their anti-tumor 
Fig. 3 T cell sub-population profile of mice before and after recombinant protein vaccination. a CD3+ T cells, b CD4+ T cells, c CD8+ T cells and  
d CD20+ cells
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cell effect through CTL responses as well as the inhibition 
of tumorgenesis and metastasis. In this study, we studied 
whether recombinant MAGE1-MAGE3-TBHSP70 pro-
tein vaccine targeting two members of MAGE family 
proteins at the same time can induce cellular cytotoxic-
response toward tumor cells and whether such strategy 
could be an effective on in decelerate the tumor growth 
rate and prolong the survival rate in  vivo in a PBL-Hu-
SCID model.
We found that the truncated forms of MAGE1 and 
MAGE3 used in this study elicited enough anti-tumor 
reaction and improved the potency of the therapeutic 
effects. Comparing with rM1H and rM3H vaccine which 
target single MAGE family member, the notable feature 
Fig. 4 Tumor cell lysis effect induced by CTLs in mice with or without vaccination. a After HepG2 tumor cells treatment, b after A549 tumor cells 
treatment and c after HHCC tumor cells treatment. E effector cells, T target cells
Fig. 5 Tumor growth curve reflected by tumor volume and Kaplan–Meier survival curve. a–c Tumor volume of rM1H, rM3H, MMH and PBS mice 
challenged with HepG2 (a), A549 (b) and HHCC (c) cells. d–f Kaplan–Meier survival curve of rM1H, rM3H, MMH and PBS mice challenged with 
HepG2 (d), A549 (e) and HHCC (f) cell lysate
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of rMMH vaccine is that it includes the CTL epitopes of 
both MAGEA family members, MAGE1 and MAGE3, 
which could significantly increase immune-surveillance 
and inhibit tumorigenesis.
We have noted that the molecular weight of the recom-
binant proteins defined in the present study is signifi-
cantly different from the mass weight predicted on the 
basis of the sequence. A possible explanation is that 
recombinant proteins migrate in an anomalous fashion 
in polyacrylamide gel. The deduced MAGE amino acid 
composition reveals a high content in acidic residues, 
which may reduce Sodium dodecyl sulfate binding and 
lower the polypeptide mobility during electrophoresis. 
Posttranslational modifications, e.g., phosphorylation or 
glycosylation of the protein could also count for the dif-
ferent in the molecular weight.
We observed a difference of spleen immune cell profile 
between normal human spleen and SCID mice or donor’s 
PBL. One explanation could be that this is resulted from 
of the irradiation and bone marrow cell depletion proce-
dure and also could be due to the feature of congenital 
immuno-deficiency in our mouse models. We did not 
pursue the further investigation of humoral immunity 
change since we would like to focus on cellular response 
in the current study. Besides, we found that the response 
of immune cells, particularly CD3 cells, by different treat-
ment groups (M1H, M3H and MMH) had a different 
magnitude. It could be interesting to further demonstrate 
these change in our future study to unravel the role of 
these vaccines on immune cells.
HHCC cell line was a commonly used liver cancer line. 
The MAGE expression of HHCC had never be tested. 
Through screen, we found that most of the members 
in MAGE family were not expressed on HHCC. How-
ever, HHCC had been regarded as a tumor cell line with 
aggressive growth rate due to its low differentiate degree 
and abolished contact inhibition effect. Thus, HHCC 
should be an ideal experimental control in this study. 
For a cell line likes HHCC which did not express MAGE 
proteins, such tumor cells would not be recognized 
by immune-cells after vaccination, and could be a safe 
approach in the future clinical practice.
Our results showed that the engrafted immune system 
could be activated by rMMH vaccine to produce suffi-
cient and specific anti-tumor reaction towards hepato-
carcinoma and pulmonary carcinomas both in  vivo and 
in vitro. By using HHCC cell line, the immune response 
in vitro and in vivo helped us distinguishing the efficiency 
of the three recombinant vaccines in this study. We found 
that rMMH vaccine had the most extensive immune 
reaction after being vaccinated to mice as it targeted both 
MAGE1 and MAGE3. Therefore, recombined MAGE1-
MAGE3-TBHSP70 should be a potential candidate for 
anti-tumor immunotherapy in the future although fur-
ther study needs to be carried out. Furthermore, this 
improved methodology for characterizing antigen pro-
files in cancer may also be helpful for the future custom-
ized anti-tumor immunotherapy.
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$  p < 0.05 vs. rM3H group
HepG2 (n = 6) A549 (n = 6) HHCC (n = 6)
rM1H 60.5 ± 18.8 23 ± 4.9 19.5 ± 5.7
rM3H 30 ± 16.5 56 ± 13 29.5 ± 7.6
rMMH 58.5 ± 19.3*$ 53 ± 15*^ 29.5 ± 8.6*
PBS 19.5 ± 4.6 20.5 ± 3.7 25.5 ± 4.4
UnHuM 13 ± 3.3 12.5 ± 4.1 9.5
Page 9 of 9Junwei et al. Cancer Cell Int  (2016) 16:45 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
carcinomas and their relationship with immune cell infiltration. Lung. 
2009;187(6):401–11.
 4. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard 
M, et al. Cancer/testis genes in multiple myeloma: expression patterns 
and prognosis value determined by microarray analysis. J Immunol. 
2007;178(5):3307–15.
 5. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, 
et al. Cancer-testis antigen expression in triple-negative breast cancer. 
Ann Oncol. 2011;22(1):98–103.
 6. Peng JR, Chen HS, Mou DC, Cao J, Cong X, Qin LL, et al. Expression of 
cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its 
correlation with clinical parameters. Cancer Lett. 2005;219(2):223–32.
 7. Steele JC, Rao A, Marsden JR, Armstrong CJ, Berhane S, Billingham LJ, 
et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA 
encoding melan A and gp100 for patients with metastatic melanoma. 
Gene Ther. 2011;18(6):584–93.
 8. Geldmacher A, Freier A, Losch FO, Walden P. Therapeutic vaccination for 
cancer immunotherapy: antigen selection and clinical responses. Hum 
Vaccin. 2011;7(Supp l):115–9.
 9. Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, 
et al. Heteroclitic serological response in esophageal and prostate 
cancer patients after NY-ESO-1 protein vaccination. Int J Cancer. 
2012;130(3):584–92.
 10. Ye J, Chen GS, Song HP, Li ZS, Huang YY, Qu P, et al. Heat shock protein 
70/MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific 
cellular immune responses in vivo. Cancer Immunol Immunother. 
2004;53(9):825–34.
 11. Ma JH, Sui YF, Ye J, Huang YY, Li ZS, Chen GS, et al. Heat shock protein 
70/MAGE-3 fusion protein vaccine can enhance cellular and humoral 
immune responses to MAGE-3 in vivo. Cancer Immunol Immunother. 
2005;54(9):907–14.
 12. Adams E, Britton W, Morgan A, Sergeantson S, Basten A. Individuals from 
different populations identify multiple and diverse T-cell determinants on 
mycobacterial HSP70. Scand J Immunol. 1994;39(6):588–96.
 13. Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, et al. Evaluation of 
MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissem-
ination of hepatocellular carcinoma cells. Br J Cancer. 2002;86(1):110–6.
 14. Sandhu J, Shpitz B, Gallinger S, Hozumi N. Human primary immune 
response in SCID mice engrafted with human peripheral blood lympho-
cytes. J Immunol. 1994;152(8):3806–13.
 15. Cao T, Leroux-Roels G. Antigen-specific T cell responses in human periph-
eral blood leucocyte (hu-PBL)-mouse chimera conditioned with radiation 
and an antibody directed against the mouse IL-2 receptor beta-chain. 
Clin Exp Immunol. 2000;122(1):117–23.
 16. Kariyama K, Higashi T, Kobayashi Y, Nouso K, Nakatsukasa H, Yamano T, 
et al. Expression of MAGE-1 and -3 genes and gene products in human 
hepatocellular carcinoma. Br J Cancer. 1999;81(6):1080–7.
 17. Marcar L, Maclaine NJ, Hupp TR, Meek DW. Mage-A cancer/testis antigens 
inhibit p53 function by blocking its interaction with chromatin. Cancer 
Res. 2010;70(24):10362–70.
 18. Liu W, Cheng S, Asa SL, Ezzat S. The melanoma-associated antigen A3 
mediates fibronectin-controlled cancer progression and metastasis. 
Cancer Res. 2008;68(19):8104–12.
